Condition:   Pancreatic Neuroendocrine Cancer
Intervention:   Other: MRI
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified May 2012

Condition:   Ankylosing Spondyloarthritis
Interventions:   Drug: Apremilast tablet 20 mg;   Drug: Apremilast tablet 30 mg BID;   Drug: Placebo
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified May 2012

Conditions:   Brain Neoplasms;   Central Nervous System Neoplasms
Interventions:   Drug: TPI287;   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Archer Biosciences, Inc.
Not yet recruiting - verified April 2012

Condition:   Renal Cancer
Intervention:   Drug: 124IcG250
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Wilex
Recruiting - verified April 2012

Conditions:   Cutaneous T Cell Lymphomas (CTCL);   Mycosis Fungoides (MF)
Interventions:   Drug: IL-12 plasmid;   Device: Electroporation
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   OncoSec Medical Incorporated
Not yet recruiting - verified April 2012

Condition:   HIV Infections
Interventions:   Biological: HIV-MAG vaccine;   Biological: IL-12 pDNA adjuvant;   Biological: VSV HIV gag vaccine;   Biological: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: Lenalidomide
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   Celgene Corporation
Not yet recruiting - verified April 2012

Conditions:   Patients Must Have Histologically or Cytologically Confirmed Non-squamous Cell, Non Small Cell Carcinoma of the Lung.;   Patient Must Have Measurable Stage IV Disease (Includes M1a, M1b Stages or Recurrent Disease).
Interventions:   Drug: Paclitaxel, Carboplatin, Bevacizumab, and Metformin;   Drug: Paclictaxl, Carboplatin, and Bevcizumab.
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Lymphoma
Intervention:   Drug: Lenalidomide
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified April 2012

Conditions:   Breast Cancer;   Obesity
Intervention:   Behavioral: Exercise
Sponsors:   University of Mississippi Medical Center;   University of Mississippi Medical Center
Recruiting - verified April 2012

Conditions:   Multiple Myeloma;   Smoldering Multiple Myeloma;   Monoclonal Gammopathy of Undetermined Significance
Intervention:   Drug: Fluciclatide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Diabetic Macular Edema.;   Non-proliferative Diabetic Retinopathy;   Proliferative Diabetic Retinopathy
Interventions:   Drug: dexamethasone intravitreal implant;   Drug: intravitreal bevacizumab
Sponsors:   Retina Macula Institute;   Retina Macula Institute;   Allergan
Recruiting - verified April 2012

Conditions:   Glioblastoma;   Glioblastoma Multiforme
Intervention:   Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors:   Tracon Pharmaceuticals Inc.;   Tracon Pharmaceuticals Inc.
Not yet recruiting - verified May 2012

Condition:   Healthy
Interventions:   Drug: Apremilast;   Drug: Rifampin
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified March 2012

Conditions:   Scleroderma, Systemic;   Sclerosis, Systemic;   Systemic Scleroderma;   Systemic Sclerosis
Interventions:   Drug: Pomalidomide (CC-4047);   Drug: Placebo
Sponsors:   Celgene Corporation;   Celgene Corporation
Not yet recruiting - verified April 2012

Condition:   Venous Leg Ulcers
Intervention:   Device: MIST Therapy
Sponsors:   Celleration, Inc.;   Celleration, Inc.
Not yet recruiting - verified March 2012

Conditions:   Prostatic Neoplams;   Prostate Cancer;   Neoplasm, Prostate;   Neoplasm,Prostatic
Interventions:   Drug: AMG 386;   Drug: Abiraterone;   Drug: Prednisone
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Brain and Central Nervous System Tumors;   Neurofibromatosis Type 1
Intervention:   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Advanced Cancers
Interventions:   Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Recurrent Glioma
Interventions:   Drug: Bevacizumab;   Drug: Minocycline;   Radiation: Radiation
Sponsors:   University of Utah;   University of Utah
Not yet recruiting - verified April 2012

Condition:   Stage IIIC Ovarian Cancer
Interventions:   Biological: FANG™ Vaccine;   Drug: Bevacizumab
Sponsors:   Gradalis, Inc.;   Gradalis, Inc.
Recruiting - verified May 2012

Condition:   Carcinoma, Squamous Cell of Head and Neck
Intervention:   Drug: Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
Sponsors:   The University of Texas Health Science Center at San Antonio;   The University of Texas Health Science Center at San Antonio
Recruiting - verified April 2012

Condition:   Colorectal Cancer
Interventions:   Procedure: Surgical resection of recurrent colorectal cancer;   Drug: Chemokine-modulatory (CKM) regimen
Sponsors:   University of Pittsburgh;   University of Pittsburgh
Not yet recruiting - verified March 2012

Condition:   Multiple Myeloma
Interventions:   Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide);   Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan);   Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan);   Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide);   Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12);   Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
Sponsors:   University of Iowa;   University of Iowa;   National Cancer Institute (NCI)
Not yet recruiting - verified March 2012

Conditions:   Recurrent/Refractory CNS;   Intraocular Lymphoma
Interventions:   Drug: Lenalidomide;   Drug: Rituximab
Sponsors:   University of California, San Francisco;   James Rubenstein;   University of California, San Francisco;   Celgene Corporation;   Genentech
Not yet recruiting - verified March 2012

Condition:   AL Amyloidosis
Interventions:   Drug: Pomalidomide;   Drug: Dexamthasone
Sponsors:   Boston Medical Center;   Boston Medical Center;   Celgene Corporation
Not yet recruiting - verified February 2012

Conditions:   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions:   Biological: trebananib;   Drug: cytarabine;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified March 2012

Condition:   Brain Tumors
Intervention:  
Sponsors:   Beth Israel Deaconess Medical Center;   Beth Israel Deaconess Medical Center;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Pomalidomide;   Drug: Pegylated Liposomal Doxorubicin (PLD);   Drug: Dexamethasone
Sponsors:   Oncotherapeutics;   Oncotherapeutics;   Celgene Corporation
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: carfilzomib;   Drug: Dexamethasone;   Drug: Clarithromycin;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Lenalidomide
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University;   Onyx Therapeutics, Inc.
Not yet recruiting - verified March 2012

Condition:   Proliferative Diabetic Retinopathy
Intervention:   Drug: Propranolol
Sponsors:   University of Wisconsin, Madison;   University of Wisconsin, Madison
Recruiting - verified February 2012

Condition:   Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Siltuximab;   Drug: Dexamethasone;   Behavioral: Questionnaires
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Janssen Services, LLC
Recruiting - verified May 2012

Condition:   Stage IV Non-small Cell Lung Cancer
Interventions:   Drug: erlotinib;   Biological: bevacizumab;   Other: laboratory biomarker analysis
Sponsors:   Academic and Community Cancer Research United;   Academic and Community Cancer Research United
Not yet recruiting - verified February 2012

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: azacitidine;   Drug: lenalidomide;   Drug: vorinostat
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Anemia, Sickle Cell
Intervention:   Drug: pomalidomide
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified January 2012

Conditions:   Neoplasms;   Cancer
Interventions:   Drug: VGX-100;   Drug: Bevacizumab
Sponsors:   Circadian Technologies Ltd.;   Circadian Technologies Ltd.
Recruiting - verified March 2012

Conditions:   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions:   Drug: dalteparin;   Drug: lenalidomide;   Drug: dexamethasone;   Other: laboratory biomarker analysis
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center;   National Cancer Institute (NCI);   Celgene Corporation
Recruiting - verified January 2012

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Drug: Temsirolimus
Sponsors:   Dartmouth-Hitchcock Medical Center;   Dartmouth-Hitchcock Medical Center
Recruiting - verified January 2012

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: FOLFOX + bevacizumab;   Dietary Supplement: Vitamin D;   Dietary Supplement: Vitamin D
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Conditions:   Gastrinoma;   Glucagonoma;   Insulinoma;   Pancreatic Polypeptide Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Pancreatic Cancer;   Somatostatinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions:   Drug: capecitabine;   Drug: temozolomide;   Biological: bevacizumab
Sponsors:   Stanford University;   Stanford University;   National Cancer Institute (NCI)
Not yet recruiting - verified January 2012

Condition:   Multiple Myeloma
Interventions:   Drug: ACE-011;   Drug: Lenalidomide;   Drug: Dexamethasone
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified May 2012

Conditions:   Glioblastoma;   Small Cell Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Glioblastoma With Oligodendroglial Component;   Recurrent Glioblastoma;   Relapsed Glioblastoma
Interventions:   Drug: Bevacizumab;   Drug: Rindopepimut (CDX-110) with GM-CSF;   Drug: KLH
Sponsors:   Celldex Therapeutics;   Celldex Therapeutics
Recruiting - verified May 2012

Condition:   Melanoma
Interventions:   Biological: Plasmid INTERLEUKIN-12;   Device: Intratumoral Electroporation
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   OncoSec Medical Incorporated
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
Sponsors:   Celgene Corporation;   Celgene Corporation;   Multiple Myeloma Research Consortium
Recruiting - verified April 2012

Conditions:   Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL)
Interventions:   Drug: High Dose Methylprednisolone;   Drug: Ofatumumab;   Drug: Lenalidomide;   Drug: Sargramostim
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   GlaxoSmithKline;   Celgene Corporation
Recruiting - verified January 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: RO5490258;   Drug: bevacizumab [Avastin];   Drug: pemetrexed;   Drug: Placebo;   Drug: cisplatin/carboplatin;   Drug: paclitaxel
Sponsors:   Genentech;   Genentech
Not yet recruiting - verified January 2012

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions:   Drug: High Dose Methylprednisolone;   Drug: Ofatumumab;   Drug: Lenalidomide;   Drug: Sargramostim
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   GlaxoSmithKline;   Celgene Corporation
Recruiting - verified January 2012

Condition:   Sarcoma, Kaposi
Intervention:   Drug: Pomalidomide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: GDC-0941;   Drug: carboplatin;   Drug: paclitaxel;   Drug: bevacizumab;   Drug: Placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified February 2012

Conditions:   Neuroblastoma;   Sarcoma
Intervention:   Drug: Cyclophosphamide, Topotecan, and Bevacizumab
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Genentech;   Children's Mercy Hospital Kansas City;   Penn State University;   University of Colorado Health Sciences Center and The Children's Hospital;   Johns Hopkins Medical Center Sidney Kimmel Comprehensive Cancer Center;   Phoenix Children's Hospital Center for Cancer & Blood Disorders;   Alberta Children's Hospital;   MD Anderson Cancer Center Orlando;   M.D. Anderson Cancer Center
Recruiting - verified December 2011

Conditions:   Melanoma;   Metastatic Melanoma
Interventions:   Drug: Vemurafenib;   Drug: Bevacizumab
Sponsors:   Melanoma Research Foundation Breakthrough Consortium;   Melanoma Research Foundation Breakthrough Consortium;   Genentech
Not yet recruiting - verified April 2012

Conditions:   HIV Infections;   Hepatitis C
Interventions:   Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Bendamustine;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone
Sponsors:   Loyola University;   Loyola University
Recruiting - verified December 2011

Condition:   Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Interventions:   Drug: MEDI-573 (1 of 2 doses);   Drug: Sorafenib
Sponsors:   MedImmune LLC;   MedImmune LLC
Recruiting - verified April 2012

Condition:   Colorectal Cancer
Interventions:   Drug: Tivozanib;   Drug: Bevacizumab;   Drug: mFOLFOX6
Sponsors:   Astellas Pharma Inc;   Astellas Pharma Inc;   AVEO Pharmaceuticals, Inc.
Recruiting - verified March 2012

Condition:   Follicular Lymphoma
Interventions:   Drug: Rituximab;   Drug: Lenalidomide;   Drug: Rituximab-CHOP;   Drug: Rituximab-CVP;   Drug: Rituximab-Bendamustine
Sponsors:   Celgene Corporation;   Celgene Corporation;   Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique
Recruiting - verified April 2012

Conditions:   Exudative Macular Degeneration;   Diabetic Macular Edema
Interventions:   Drug: Avastin;   Drug: Avastin;   Drug: Lucentis
Sponsors:   Vitreo-Retinal Associates, Michigan;   Vitreo-Retinal Associates, Michigan;   Van Andel Research Institute
Recruiting - verified November 2011

Conditions:   Branch Retinal Vein Occlusion;   Central Retinal Vein Occlusion;   Macular Edema
Interventions:   Drug: ranibizumab 0.5mg;   Drug: ranibizumab 1.0mg
Sponsors:   Hanscom, Thomas, M.D.;   Hanscom, Thomas, M.D.;   Genentech
Recruiting - verified November 2011

Conditions:   Sarcoma;   Stomach Neoplasms;   Neoplasms
Interventions:   Drug: Pazopanib;   Drug: ARQ 197
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Head and Neck Cancer
Interventions:   Biological: cetuximab;   Biological: recombinant interleukin-12;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Arthur G. James Cancer Hospital & Richard J. Solove Research Institute;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Colorectal Cancer
Interventions:   Drug: Axitinib;   Drug: Bevacizumab;   Drug: 5-FU;   Drug: 5-FU;   Drug: Leucovorin;   Drug: Oxaliplatin
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Pfizer
Recruiting - verified January 2012

Conditions:   Glioblastoma Multiforme;   Gliosarcoma;   Anaplastic Astrocyloma;   Oligoastrocytoma;   Malignant Glioma
Intervention:   Drug: AZD7451
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Glioblastoma Multiforme
Intervention:   Drug: Avastin
Sponsors:   Brain & Spine Surgeons of New York;   Brain & Spine Surgeons of New York
Recruiting - verified February 2012

Condition:   Hepatitis C, Genotype 1
Interventions:   Drug: BMS-790052 (Daclatasvir);   Drug: Ribavirin;   Drug: Peg-Interferon alfa 2a
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified April 2012

Condition:   Diabetic Macular Edema
Interventions:   Drug: Ranibizumab;   Drug: Ranibizumab
Sponsors:   Vitreo-Retinal Associates, PC;   Vitreo-Retinal Associates, PC;   Genentech
Recruiting - verified January 2012

Condition:   Colorectal Cancer, Metastatic
Interventions:   Other: Pharmacokinetic 5-FU dose adjustment using OnDose® assay;   Other: Standard of care
Sponsors:   Myriad Genetic Laboratories, Inc.;   Myriad Genetic Laboratories, Inc.
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Intervention:   Drug: lenalidomide
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Montefiore Medical Center;   State University of New York - Downstate Medical Center;   NYU MEDICAL CENTER;   University of Rochester;   Weill Medical College of Cornell University;   Stamford Hospital
Recruiting - verified March 2012

Condition:   Chronic Lymphocytic Leukemia
Intervention:   Drug: Maintenance lenalidomide
Sponsors:   Yale University;   Yale University;   Celgene Corporation
Recruiting - verified March 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: sunitinib malate;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Renal Cell Carcinoma;   Clear-cell Metastatic Renal Cell Carcinoma
Interventions:   Biological: BMS-936558;   Drug: Sunitinib;   Drug: Pazopanib
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Ono Pharmaceutical Company, Ltd.
Recruiting - verified March 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Carfilzomib;   Drug: Pomalidomide;   Drug: Dexamethasone
Sponsors:   Academic Myeloma Consortium;   Academic Myeloma Consortium;   CORE Science Solutions;   Onyx Pharmaceuticals;   Celgene Corporation
Recruiting - verified February 2012

Conditions:   Adult Lymphocyte Depletion Hodgkin Lymphoma;   Adult Lymphocyte Predominant Hodgkin Lymphoma;   Adult Mixed Cellularity Hodgkin Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Adult Nodular Sclerosis Hodgkin Lymphoma;   Recurrent Adult Hodgkin Lymphoma
Interventions:   Drug: panobinostat;   Drug: lenalidomide
Sponsors:   Ohio State University Comprehensive Cancer Center;   Ohio State University Comprehensive Cancer Center;   Celgene Corporation;   Novartis
Recruiting - verified February 2012

Conditions:   Retinal Vein Occlusion;   Macular Edema
Interventions:   Drug: Ozurdex;   Drug: Ozurdex
Sponsors:   Retina Macula Institute;   Retina Macula Institute;   Allergan
Recruiting - verified April 2012

Condition:   Hepatitis C
Interventions:   Drug: BMS-790052 (NS5A Replication Complex Inhibitor);   Drug: Placebo matching BMS-790052;   Drug: Pegylated-interferon alfa 2a;   Drug: Pegylated-interferon alfa 2a;   Drug: Ribavirin;   Drug: Ribavirin
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Condition:   Solid Tumors
Interventions:   Drug: Bevacizumab;   Drug: Dasatinib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Drug: Rituximab;   Drug: Lenalidomide
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
Recruiting - verified December 2011

Condition:   Radiation Therapy
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Hepatitis;   HIV/AIDS
Interventions:   Drug: Boceprevir;   Drug: Peg-Interferon-alfa 2B;   Drug: Ribavirin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011

Conditions:   Hepatitis C;   Medication Adherence
Interventions:   Other: enhanced DOT (both pegylated interferon alfa-2a and ribavirin);   Other: standard DOT (PEG-DOT control arm)
Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   Albert Einstein College of Medicine of Yeshiva University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified September 2011

Conditions:   Ureteral Neoplasms;   Urinary Bladder Neoplasms;   Urethral Neoplasms
Interventions:   Drug: Lenalidomide;   Drug: Cisplatin;   Drug: Gemcitabine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Recurrent Neuroendocrine Carcinoma of the Skin;   Stage I Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions:   Biological: interleukin-12 gene;   Biological: electroporation-mediated plasmid DNA vaccine therapy;   Other: laboratory biomarker analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Leukemia;   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS)
Interventions:   Drug: Azacitidine;   Drug: Lenalidomide
Sponsors:   Stanford University;   Stanford University;   Celgene Corporation
Recruiting - verified September 2011

Condition:   Myeloma
Interventions:   Drug: Panobinostat;   Drug: Bortezomib;   Drug: Lenalidomide;   Drug: Dexamethasone;   Behavioral: Symptom Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Novartis
Not yet recruiting - verified March 2012

Condition:   Carotid Stenosis
Intervention:   Drug: [F-18]RDG-K5
Sponsors:   Siemens Molecular Imaging;   Siemens Molecular Imaging
Recruiting - verified May 2012

Condition:   Glioblastoma Multiforme
Intervention:   Drug: Temozolomide, bevacizumab and bortezomib
Sponsors:   Emory University;   Emory University
Recruiting - verified March 2012

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention:   Drug: Lenalidomide
Sponsors:   University of California, Davis;   University of California, Davis;   Celgene Corporation
Not yet recruiting - verified April 2012

Condition:   Myeloma
Interventions:   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Cyclophosphamide
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Celgene Corporation
Recruiting - verified May 2012

Conditions:   Retinal Vein Occlusion;   Macular Edema
Interventions:   Drug: Intravitreal injection of bevacizumab;   Drug: Intravitreal injection of ranibizumab (0.5 mg per dose)
Sponsors:   Barnes Retina Institute;   Barnes Retina Institute;   Retina Associates of Florida, P.A.;   Illinois Retina Associates;   Kresge Eye Institute;   Long Island Vitreoretinal Consultants;   Mid Atlantic Retina;   Retina Associates, Kansas City;   Massachusetts Eye and Ear Infirmary
Recruiting - verified February 2012

Condition:   Rectal Cancer Patients
Intervention:   Other: Bevacizumab 5 mg/kg
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified August 2011

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Biological: PF-04856884;   Drug: AG-013736
Sponsors:   Pfizer;   Pfizer
Recruiting - verified April 2012

Condition:   Colorectal Cancer
Interventions:   Drug: onartuzumab [MetMAb];   Drug: Placebo;   Drug: bevacizumab [Avastin];   Drug: FOLFOX regimen;   Drug: leucovorin;   Drug: 5-FU
Sponsors:   Genentech;   Genentech;   Sarah Cannon Research Institute
Recruiting - verified January 2012

Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions:   Drug: lenalidomide;   Biological: rituximab;   Other: pharmacological study;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Glioblastoma;   Brain Neoplasm
Intervention:   Procedure: Craniotomy
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified April 2012

Condition:   Melanoma
Interventions:   Drug: Ipilimumab;   Drug: Temozolomide;   Drug: Cisplatin;   Drug: Interferon Alfa-2b;   Drug: Interleukin-2
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Not yet recruiting - verified February 2012

Conditions:   Telangiectasia, Hereditary Hemorrhagic;   Epistaxis
Interventions:   Drug: Sterile saline;   Drug: Bevacizumab;   Drug: Estriol;   Drug: Tranexamic Acid
Sponsors:   Georgia Health Sciences University;   James Gossage;   Hereditary Hemorrhagic Telangiectasia Foundation International
Recruiting - verified February 2012

Condition:   Keloid
Intervention:   Biological: bevacizumab
Sponsors:   Tirgan, Michael H., M.D.;   Tirgan, Michael H., M.D.
Recruiting - verified February 2012

Conditions:   Chronic Hepatitis C;   Genotype 1
Interventions:   Procedure: Educational Intervention;   Other: No Intervention
Sponsors:   Chronic Liver Disease Foundation;   Chronic Liver Disease Foundation;   Clinical Development Group
Recruiting - verified February 2012

Conditions:   Neurofibromatosis;   NF1;   Plexiform Neurofibromas
Intervention:   Drug: Sutent®/Sunitinib
Sponsors:   Indiana University;   Indiana University;   Department of Defense;   Pfizer
Recruiting - verified March 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Carfilzomib;   Drug: Lenalidomide;   Drug: Dexamethasone
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI);   Celgene Corporation;   Onyx Therapeutics, Inc.
Recruiting - verified July 2011

Condition:   HIGH GRADE GLIOMA
Interventions:   Drug: TH-302;   Drug: Placebo
Sponsors:   Threshold Pharmaceuticals;   Threshold Pharmaceuticals;   The University of Texas Health Science Center at San Antonio
Recruiting - verified July 2011

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: bevacizumab;   Drug: MEGF0444A;   Drug: mFOLFOX6;   Drug: placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Conditions:   Leukemia;   Adult Acute Lymphocytic Leukemia
Intervention:   Drug: lenalidomide
Sponsors:   Stanford University;   Stanford University;   Celgene Corporation
Recruiting - verified July 2011

Condition:   Renal Cell Carcinoma
Intervention:   Drug: everolimus and bevacizumab
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Novartis Pharmaceuticals
Recruiting - verified March 2012

Condition:   Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention:   Drug: Submucosal Bevacizumab
Sponsors:   University of California, San Diego;   University of California, San Diego
Recruiting - verified July 2011

Condition:   Hereditary Hemorrhagic Telangiectasia (HHT)
Intervention:   Drug: Bevacizumab
Sponsors:   University of California, San Diego;   University of California, San Diego
Recruiting - verified July 2011

Condition:   Sarcoma, Alveolar Soft Part
Interventions:   Drug: Cediranib;   Drug: Sunitinib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Drug: Lenalidomide;   Drug: Lenalidomide
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified October 2011

Conditions:   Brain Cancer;   MALIGNANT GLIOMA;   Glioblastoma;   Anaplastic Astrocytoma (AA);   Anaplastic Oligodendroglioma (AO);   Anaplastic Oligo-astrocytoma (AOA);   Anaplastic Mixed Gliomas;   Malignant Glioma NOS
Intervention:   Other: Bevacizumab & stereotactic radiotherapy
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Genentech;   Columbia University;   University of California, San Francisco
Recruiting - verified April 2012

Condition:   Leukemia
Intervention:   Drug: PEG-IFNá-2a
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified February 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: GSK2336805;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin;   Drug: GSK2336805 Matching Placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline;   Pharmaceutical Product Development Clinical Research Organization (CRO)
Recruiting - verified February 2012

Condition:   Metastatic Clear Cell Renal Cell Carcinoma
Interventions:   Drug: LY2510924;   Drug: Sunitinib
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified April 2012

Condition:   Hepatitis C
Interventions:   Drug: BMS-790052 (NS5A Replication Complex Inhibitor);   Drug: Peg-Interferon Alfa-2a;   Drug: Ribavirin
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Condition:   Multiple Myeloma
Intervention:   Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: FOLFIRI-bevacizumab regimen;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: sorafenib tosylate
Sponsors:   National Cancer Institute (NCI);   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Conditions:   Advanced Renal Cell Carcinoma;   Gastrointestinal Stromal Tumors
Intervention:   Drug: TH-302
Sponsors:   Threshold Pharmaceuticals;   Threshold Pharmaceuticals
Recruiting - verified July 2011

Condition:   Relapsed Multiple Myeloma
Interventions:   Drug: Lenalidomide 15mg;   Drug: Lenalidomide 25mg
Sponsors:   Boston VA Research Institute, Inc.;   Boston VA Research Institute, Inc.;   Celgene Corporation;   Kansas City Veteran Affairs Medical Center;   VA Pittsburgh Healthcare System;   VA Greater Los Angeles Healthcare System;   Michael Debakey Veterans Affairs Medical Center;   Edward Hines Jr. VA Hospital
Recruiting - verified September 2011

Conditions:   Glioblastoma;   Gliosarcoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Oligoastrocytoma
Intervention:   Drug: BIBF 1120
Sponsors:   Dana-Farber Cancer Institute;   Patrick Y. Wen, MD;   Boehringer Ingelheim Pharmaceuticals;   Wake Forest University Baptist Medical Center;   Dartmouth-Hitchcock Medical Center;   University of Virginia;   Massachusetts General Hospital
Not yet recruiting - verified December 2011

Condition:   Low and Intermediate 1 Risk MDS
Intervention:   Drug: Lenalidomide and azacitidine combination
Sponsors:   Rush University Medical Center;   Rush University Medical Center;   Celgene Corporation
Recruiting - verified June 2011

Condition:   Colorectal Cancer
Interventions:   Drug: bevacizumab;   Drug: FOLFIRI regimen;   Drug: mFOLFOX6
Sponsors:   Genentech;   Genentech
Recruiting - verified December 2011

Conditions:   Hepatocellular Carcinoma;   Hepatocellular Cancer;   Carcinoma, Hepatocellular
Intervention:   Drug: TRC105
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Myeloproliferative Diseases
Interventions:   Drug: Ruxolitinib;   Drug: Lenalidomide;   Drug: Prednisone
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Incyte Corporation
Recruiting - verified March 2012

Condition:   Bladder Cancer
Interventions:   Drug: bacilli calmette-guerin (BCG);   Drug: lenalidomide
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Celgene Corporation
Recruiting - verified April 2012

Conditions:   Glioblastoma Multiforme;   Anaplastic Astrocytoma
Interventions:   Drug: Bevacizumab and Carboplatin;   Drug: Bevacizumab and Carboplatin
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified December 2011

Condition:   Leukemia, Lymphocytic, Chronic, B-Cell
Intervention:   Drug: Lenalidomide + Plerixafor (+ Rituximab)
Sponsors:   Duke University;   Duke University;   Celgene Corporation;   Genzyme
Recruiting - verified January 2012

Condition:   Hepatitis B
Interventions:   Drug: Tenofovir;   Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Pittsburgh
Not yet recruiting - verified February 2012

Conditions:   Colorectal Cancer;   Colorectal Adenocarcinoma
Interventions:   Drug: Brivanib;   Drug: Irinotecan
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
Recruiting - verified May 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: MEGF0444A;   Drug: paclitaxel;   Drug: placebo
Sponsors:   Genentech;   Genentech
Recruiting - verified March 2012

Conditions:   Patients With Renal Cell Carcinoma Who Are Newly Initiating Therapy;   With the Oral Tyrosine-kinase Inhibitor Sunitinib.
Intervention:  
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania;   Vanderbilt University;   Case Medical Center;   University of Wisconsin, Madison
Recruiting - verified May 2011

Conditions:   Acute Myeloid Leukemia;   Acute Myelogenous Leukemia
Interventions:   Drug: Azacitidine;   Drug: Lenalidomide - single agent;   Drug: Lenalidomide in combination
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Amrubicin;   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Aspirin
Sponsors:   Stanford University;   Stanford University;   Celgene Corporation
Recruiting - verified October 2011

Condition:   Diabetic Ulcer
Intervention:   Drug: AMD3100 injection + rhPDGF-BB topical
Sponsors:   New York University School of Medicine;   New York University School of Medicine;   National Institutes of Health (NIH);   Genzyme
Not yet recruiting - verified May 2011

Condition:   Multiple Myeloma
Interventions:   Biological: Anti-CXCR4 (BMS-936564);   Biological: Lenalidomide;   Biological: Dexamethasone;   Biological: Anti-CXCR4 (BMS-936564);   Biological: Bortezomib;   Biological: Dexamethasone
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified August 2011

Conditions:   Urethral Neoplasms;   Neoplasms, Urethral;   Ureter Cancer;   Cancer of the Urethra;   Urethral Cancer
Interventions:   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Lenalidomide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Bacterial Infection;   Leukemia;   Lymphoma
Interventions:   Biological: pneumococcal polyvalent vaccine;   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   Arthur G. James Cancer Hospital & Richard J. Solove Research Institute;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab [Avastin];   Drug: Standard of care treatment
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified April 2012

Condition:   Renal Cell Carcinoma
Interventions:   Biological: BMS-936558;   Biological: BMS-936558;   Biological: BMS-936558
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Ono Pharma
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Biological: Allogeneic Myeloma Vaccine
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Celgene Corporation
Recruiting - verified March 2012

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: Lenalidomide;   Drug: Sorafenib
Sponsors:   Indiana University;   Indiana University School of Medicine;   Celgene Corporation
Recruiting - verified December 2011

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: erlotinib hydrochloride;   Drug: pemetrexed disodium
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Glioblastoma Multiforme
Interventions:   Drug: Bevacizumab;   Drug: BKM120
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Novartis
Recruiting - verified March 2012

Condition:   Metastatic Urothelial Carcinoma
Intervention:   Drug: Lenalidomide
Sponsors:   Mount Sinai School of Medicine;   Mount Sinai School of Medicine;   Celgene Corporation
Recruiting - verified October 2011

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Drug: Dexamethasone;   Biological: Elotuzumab (BMS-901608; HuLuc63);   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified October 2011

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B Chronic Lymphocytic Leukemia
Interventions:   Drug: Lenalidomide;   Drug: Bendamustine;   Drug: Rituximab
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
Recruiting - verified February 2012

Condition:   Adult Solid Tumor
Intervention:   Drug: TRC105 and Bevacizumab
Sponsors:   Tracon Pharmaceuticals Inc.;   Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012

Conditions:   High Grade Glioma: Glioblastoma (GBM);   High Grade Glioma: Gliosarcoma;   Anaplastic Astrocytoma (AA);   Anaplastic Oligodendroglioma (AO);   Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions:   Drug: Plerixafor;   Drug: Plerixafor;   Drug: Bevacizumab;   Drug: Plerixafor;   Procedure: Surgery
Sponsors:   Dana-Farber Cancer Institute;   Patrick Y. Wen, MD;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Genzyme
Recruiting - verified February 2012

Condition:   Solid Cancers
Interventions:   Drug: bevacizumab;   Drug: capecitabine;   Drug: GDC-0980;   Drug: mFOLFOX6
Sponsors:   Genentech;   Genentech
Recruiting - verified February 2012

Condition:   Mantle Cell Lymphoma
Interventions:   Drug: lenalidomide;   Biological: rituximab
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University;   Celgene Corporation
Recruiting - verified November 2011

Condition:   Colon Cancer
Interventions:   Drug: chemotherapy and GI-4000;   Drug: GI-4000
Sponsors:   Georgetown University;   Georgetown University;   GlobeImmune
Recruiting - verified February 2012

Conditions:   Liver Metastases;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions:   Drug: oxaliplatin;   Drug: leucovorin calcium;   Drug: fluorouracil;   Biological: bevacizumab;   Procedure: therapeutic conventional surgery;   Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Drug: irinotecan hydrochloride
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Intervention:   Drug: Pomalidomide
Sponsors:   Yale University;   Yale University;   Celgene Corporation
Recruiting - verified July 2011

Conditions:   Ovarian Carcinoma;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Interventions:   Biological: OC-DC vaccine;   Drug: Bevacizumab;   Drug: cyclophosphamide 300 mg/m2/d for 3 days;   Drug: fludarabine 30 mg/m2/d for 3 days;   Drug: ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified June 2011

Condition:   Hepatitis C
Interventions:   Biological: Pegylated Interferon Lambda (pegIFNλ);   Drug: BMS-790052 (NS5A Inhibitor);   Drug: Ribavirin (RBV);   Drug: BMS-650032 (NS3 Protease Inhibitor);   Biological: Pegylated Interferon Alfa-2a (pegIFNα-2a);   Biological: Pegylated Interferon Lambda (pegIFNλ);   Drug: Ribavirin (RBV);   Biological: Pegylated Interferon Lambda (pegIFNλ);   Drug: Ribavirin (RBV);   Drug: BMS-790052 (NS5A Inhibitor);   Drug: BMS-650032 (NS3 Protease Inhibitor);   Drug: Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor);   Drug: Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor);   Drug: Placebo for Ribavirin (RBV);   Drug: Placebo for Ribavirin (RBV)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified April 2012

Conditions:   Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Carcinoma, Thymic
Interventions:   Drug: AZD;   Drug: MK-2206;   Drug: Lapatinib;   Drug: Erlotinib;   Drug: Sunitinib;   Procedure: Molecular Profiling
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: fosbretabulin tromethamine
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Solid Cancers
Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: GDC-0980;   Drug: paclitaxel
Sponsors:   Genentech;   Genentech
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Sirolimus;   Drug: Tacrolimus;   Drug: Lenalidomide
Sponsors:   Indiana University;   Indiana University School of Medicine;   Celgene Corporation
Recruiting - verified January 2012

Conditions:   Brain Tumor;   Spinal Tumor;   Glial Tumour of Brain;   Ependymal Tumour of Brain;   Spinal Cord Ependymoma;   Anaplastic Ependymoma
Interventions:   Drug: Bevacizumab;   Drug: Carboplatin
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified February 2012

Condition:   HIV Infection
Intervention:   Drug: Interferon Alpha 2b
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011

Condition:   Multiple Myeloma
Intervention:   Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
Sponsors:   Hackensack University Medical Center;   Hackensack University Medical Center
Recruiting - verified December 2011

Condition:   Non Hodgkin's Lymphoma
Intervention:   Drug: REVLIMID®, Rituxan®
Sponsors:   University of California, Davis;   University of California, Davis;   Celgene Corporation
Recruiting - verified April 2012

Conditions:   HIV Infection;   Hepatitis C
Interventions:   Drug: Anti-HIV Agents;   Drug: raltegravir;   Drug: Emtricitabine and tenofovir disoproxil fumarate
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011

Condition:   Renal Cell Carcinoma
Intervention:   Drug: BKM-120 Bevacizumab
Sponsors:   Dana-Farber Cancer Institute;   Toni Choueiri, MD;   Beth Israel Deaconess Medical Center
Recruiting - verified February 2012

Condition:   Metastatic Colorectal Cancer
Interventions:   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: irinotecan hydrochloride;   Biological: bevacizumab;   Biological: cetuximab;   Drug: capecitabine;   Genetic: mutation analysis;   Genetic: gene expression analysis;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: nucleic acid sequencing;   Genetic: protein expression analysis;   Genetic: polymerase chain reaction;   Genetic: DNA analysis
Sponsors:   Fox Chase Cancer Center;   Fox Chase Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Conditions:   Cognitive/Functional Effects;   Colorectal Cancer;   Neurotoxicity
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified February 2012

Condition:   Adult T Cell Leukemia/Lymphoma
Intervention:   Drug: Lenalidomide
Sponsors:   Columbia University;   Columbia University;   Celgene Corporation
Recruiting - verified October 2011

Condition:   Melanoma (Skin)
Interventions:   Biological: ipilimumab;   Biological: recombinant interferon alfa-2b
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   HIV Infections
Interventions:   Biological: Profectus HIV MAG pDNA vaccine;   Biological: IL-12;   Other: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Biological: IMA901 plus GM-CSF;   Drug: Cyclophosphamide
Sponsors:   immatics Biotechnologies GmbH;   immatics Biotechnologies GmbH
Recruiting - verified May 2012

Condition:   Brain Cancer
Interventions:   Drug: Vorinostat;   Drug: Bevacizumab;   Drug: Bevacizumab;   Drug: Vorinostat
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Genentech
Recruiting - verified April 2012

Conditions:   Glioblastoma Multiforme;   Anaplastic Astrocytoma
Interventions:   Drug: Bevacizumab;   Drug: Bevacizumab
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified March 2012

Condition:   Lung Cancer
Interventions:   Drug: Carboplatin;   Drug: Pemetrexed;   Drug: Bevacizumab;   Drug: Cetuximab;   Drug: Cixutumumab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Eli Lilly and Company;   Genentech;   ImClone LLC
Recruiting - verified May 2012

Condition:   Lung Cancer
Intervention:   Drug: Pazopanib
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   GlaxoSmithKline
Recruiting - verified April 2012

Conditions:   High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions:   Drug: PEGASYS;   Drug: Hydroxyurea;   Drug: Aspirin
Sponsors:   Myeloproliferative Disorders-Research Consortium;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI);   Roche Pharma AG
Recruiting - verified December 2011

Conditions:   High Risk Polycythemia Vera;   High Risk Essential Thrombocythemia
Interventions:   Drug: PEGASYS;   Drug: Aspirin
Sponsors:   Myeloproliferative Disorders-Research Consortium;   Myeloproliferative Disorders-Research Consortium;   National Cancer Institute (NCI);   Roche Pharma AG
Recruiting - verified February 2012

Condition:   Neoplasms
Interventions:   Drug: EZN-2208;   Drug: Bevacizumab
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2010

Conditions:   Colorectal Cancer;   Head and Neck Cancer
Interventions:   Biological: cetuximab;   Drug: lenalidomide;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Arthur G. James Cancer Hospital & Richard J. Solove Research Institute;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   Prostate Cancer
Interventions:   Drug: Abiraterone Acetate;   Drug: Prednisone;   Drug: Sunitinib;   Drug: Dasatinib
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Bristol-Myers Squibb;   Ortho Biotech, Inc.;   Pfizer
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: GDC-0980;   Drug: paclitaxel
Sponsors:   Genentech;   Genentech
Recruiting - verified May 2012

Condition:   Advanced Myeloma.
Interventions:   Biological: Prevnar- Pneumococcal Conjugate Vaccine (PCV);   Other: Activated/costimulated autologous T-cell;   Drug: Lenalidomide;   Biological: MAGE-A3, Hiltonol® (Poly-ICLC)
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania;   University of Pennsylvania
Recruiting - verified May 2012

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: Lenalidomide 50 mg/day Days 1-28;   Drug: Lenalidomide 10 mg/day
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified October 2011

Condition:   Multiple Myeloma
Intervention:   Drug: Thalidomide+Melphalan +Bortezomib+stem cell tranplant
Sponsors:   Hackensack University Medical Center;   Hackensack University Medical Center;   Millennium Pharmaceuticals, Inc.
Recruiting - verified October 2011

Condition:   HIV-1 Infection
Interventions:   Drug: atorvastatin;   Drug: atorvastatin
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   Pfizer
Recruiting - verified September 2011

Conditions:   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Recurrent Adult Acute Myeloid Leukemia
Interventions:   Drug: cytarabine;   Drug: lenalidomide
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified January 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone;   Drug: Dexamethasone (Oral);   Drug: Dexamethasone (IV);   Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb;   Abbott Biotherapeutics Corp.
Recruiting - verified May 2012

Conditions:   Hypertension;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: lisinopril;   Drug: losartan potassium;   Other: laboratory biomarker analysis;   Drug: benazepril hydrochloride;   Drug: ramipril
Sponsors:   Comprehensive Cancer Center of Wake Forest University;   Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012

Conditions:   Choroidal Neovascularization;   Myopia;   Punctate Inner Choroidopathy (PIC);   Multifocal Choroiditis;   Ocular Histoplasmosis Syndrome;   Central Serous Chorioretinopathy (CSC);   Angioid Streaks;   Trauma, or Hereditary Eye Diseases
Interventions:   Drug: Bevacizumab (Avastin; Genentech, Inc.);   Drug: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
Sponsors:   Massachusetts Eye and Ear Infirmary;   Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012

Conditions:   Macular Edema;   Central Retinal Vein Occlusion
Interventions:   Drug: Ozurdex;   Drug: Avastin
Sponsors:   Long Island Vitreoretinal Consultants;   Long Island Vitreoretinal Consultants
Recruiting - verified April 2012

Conditions:   Islet Cell Tumor;   Pancreatic Cancer
Interventions:   Biological: bevacizumab;   Drug: everolimus;   Drug: octreotide acetate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: lenalidomide;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   NCI - Pediatric Oncology Branch;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: temsirolimus;   Drug: vinorelbine tartrate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Diffuse Intrinsic Pontine Glioma;   Anaplastic Astrocytoma;   High Grade Glioma
Interventions:   Drug: Lenalidomide;   Radiation: Radiation Therapy
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified July 2011

Conditions:   Fallopian Tubes Cancer;   Ovarian Cancer;   Peritoneal Cancer
Intervention:   Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Genentech
Recruiting - verified February 2012

Conditions:   Renal Cell Carcinoma;   Cancer
Interventions:   Drug: pazopanib;   Drug: placebo
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified May 2012

Condition:   Solid Organ Malignancies
Intervention:   Drug: Lenalidomide; Everolimus (RAD001)
Sponsors:   Emory University;   Emory University;   Celgene Corporation;   Novartis
Recruiting - verified February 2012

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: irinotecan hydrochloride;   Drug: temozolomide
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Kidney Cancer
Interventions:   Drug: Pazopanib;   Drug: Bevacizumab;   Drug: Everolimus
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified December 2011

Conditions:   Patients With Multiple Myeloma Experiencing a;   First or Second Relapse
Intervention:   Drug: IPH2101 combined to lenalidomide
Sponsors:   Innate Pharma;   Innate Pharma
Recruiting - verified October 2011

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: bortezomib;   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Advanced Cancers
Interventions:   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Hepatitis C
Intervention:   Drug: Interferon Alfa-2b
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   Tibotec Pharmaceutical Limited
Recruiting - verified February 2012

Condition:   Refractory Multiple Myeloma
Interventions:   Drug: pomalidomide;   Drug: bortezomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis;   Other: gene expression analysis
Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Exudative Age-related Macular Degeneration
Interventions:   Drug: 24GyE proton and Anti-VEGF;   Drug: 16GyE and anti-VEGF;   Drug: Sham Irradiation and anti-VEGF
Sponsors:   University of California, Davis;   University of California, Davis;   University of California, San Francisco
Recruiting - verified November 2011

Conditions:   Esophageal Carcinoma;   GE Junction Cancer
Intervention:   Drug: bevacizumab + FOLFOX
Sponsors:   Fox Chase Cancer Center;   Fox Chase Cancer Center
Recruiting - verified March 2012

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Dovitinib;   Drug: Sorafenib
Sponsors:   Novartis;   Novartis Pharmaceuticals
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Bortezomib;   Drug: Dexamethasone;   Procedure: Autologous Stem Cell Transplant
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Celgene Corporation;   Millennium Pharmaceuticals, Inc.;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center;   Emory University;   University of Michigan;   Fox Chase Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Fred Hutchinson Cancer Research Center;   Barbara Ann Karmanos Cancer Institute;   Duke University;   University of California, San Francisco;   University of Chicago;   M.D. Anderson Cancer Center;   UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011

Condition:   Head and Neck Cancer
Interventions:   Drug: cediranib maleate;   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified October 2010

Condition:   Hodgkin Disease
Intervention:   Drug: Lenalidomide
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified October 2011

Conditions:   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions:   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Biological: bevacizumab;   Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A;   Other: laboratory biomarker analysis
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Rectal Cancer;   Colon Cancer;   Metastasis;   Adenocarcinoma
Interventions:   Drug: Hydroxychloroquine;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-fluorouracil;   Drug: 5-fluorouracil;   Drug: Bevacizumab
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012

Conditions:   Ovarian Cancer;   Epithelial Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Intervention:   Drug: Lenalidomide, Liposomal Doxorubicin, Bevacizumab
Sponsors:   New Mexico Cancer Care Alliance;   New Mexico Cancer Care Alliance;   Celgene Corporation
Recruiting - verified December 2011

Condition:   Kidney Cancer
Interventions:   Biological: bevacizumab;   Drug: everolimus;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Lymphoma;   Myeloma
Interventions:   Drug: Pomalidomide;   Drug: Pomalidomide
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
Recruiting - verified February 2012

Conditions:   Solid Tumors;   Advanced Cancer
Interventions:   Drug: Anastrozole;   Drug: Bevacizumab;   Drug: Everolimus;   Drug: Sorafenib;   Drug: Erlotinib
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cancer
Interventions:   Drug: AMG 386;   Drug: AMG 386 Placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified May 2012

Condition:   Gastrointestinal Cancers
Interventions:   Drug: Capecitabine;   Drug: Oxaliplatin;   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Genentech
Recruiting - verified March 2012

Conditions:   Esophageal Cancer;   Gastric Cancer
Interventions:   Drug: bevacizumab;   Drug: trastuzumab;   Drug: oxaliplatin;   Drug: capecitabine
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Genentech
Recruiting - verified September 2011

Conditions:   Sarcoma;   Desmoplastic Small Round Cell Tumor (DSRCT)
Intervention:   Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Genentech
Recruiting - verified March 2012

Condition:   Advanced Cancer
Interventions:   Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Sorafenib;   Drug: Carboplatin
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified April 2012

Conditions:   Glioblastoma Multiforme;   Gliosarcoma
Intervention:   Drug: Gliadel, Radiation Therapy, Avastin, Temodar
Sponsors:   Duke University;   Duke University;   Genentech;   Eisai Inc.
Recruiting - verified March 2012

Condition:   Kidney Cancer
Interventions:   Drug: Everolimus;   Drug: Sunitinib
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Novartis
Recruiting - verified April 2012

Condition:   Advanced Cancers
Interventions:   Drug: Lenalidomide;   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Temsirolimus;   Drug: Lenalidomide;   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: 5-fluorouracil
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
Recruiting - verified May 2012

Condition:   Diffuse Intrinsic Pontine Glioma
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Temozolomide;   Radiation: Irradiation
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   University of California, San Francisco;   Children's Hospital Boston;   Children's Memorial Hospital;   Children's Hospital Los Angeles;   University of Utah;   Memorial Sloan-Kettering Cancer Center;   Seattle Children's Hospital;   Children's Hospital Colorad;   Doernbecher Children's Hospital;   Washington University Children's Hospital;   Miami Children's Hospital;   Johns Hopkins University;   University of Florida;   Children's Hospitals and Clinics of Minnesota;   Southwestern Regional Medical Center;   New York University;   University of Rochester;   University of Mississippi Medical Center;   Louisville Children's Hospital;   Children's Healthcare of Atlanta
Recruiting - verified September 2011

Condition:   Metastatic Colorectal Cancer
Intervention:   Drug: FOLFIRI, Avastin, Irinotecan
Sponsors:   University of Chicago;   University of Chicago;   National Institute for Cancer Research, Italy
Recruiting - verified June 2011

Condition:   Liver Cancer
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Genentech;   OSI Pharmaceuticals
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: MetMAb;   Drug: paclitaxel;   Drug: placebo
Sponsors:   Genentech;   Genentech;   Hoffmann-La Roche
Recruiting - verified March 2012

Condition:   Diffuse Large B-cell Lymphoma
Interventions:   Drug: Lenalidomide;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Rituximab;   Drug: Etoposide
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified September 2010

Condition:   Kidney Cancer
Interventions:   Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Primary Myelofibrosis
Interventions:   Drug: Pomalidomide;   Other: Placebo
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified May 2012

Conditions:   Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions:   Drug: sunitinib malate;   Other: laboratory biomarker analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Genetic: polymorphism analysis
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center
Recruiting - verified February 2012

Condition:   Refractory Multiple Myeloma
Interventions:   Drug: azacitidine;   Drug: lenalidomide;   Drug: dexamethasone;   Other: DNA methylation analysis;   Other: gene expression analysis;   Other: bone marrow aspiration;   Other: immunohistochemistry staining method;   Other: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Advanced Cancer
Interventions:   Drug: Bendamustine;   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Cephalon;   National Comprehensive Cancer Network
Recruiting - verified March 2012

Conditions:   Hepatitis C Infection;   Thrombocytopenia
Interventions:   Biological: romiplostim;   Drug: ribavirin;   Other: placebo;   Biological: PEG-interferon alfa-2a;   Other: laboratory biomarker analysis
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012

Conditions:   Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma
Interventions:   Biological: bevacizumab;   Drug: temozolomide;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: DNA methylation analysis
Sponsors:   University of California, Los Angeles;   University of California, Los Angeles;   Genentech
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide plus Melphalan during autologous stem cell transplantation;   Drug: Lenalidomide maintenance
Sponsors:   Indiana University;   Indiana University School of Medicine;   Celgene Corporation
Recruiting - verified March 2012

Condition:   Solid Cancers
Interventions:   Drug: bevacizumab;   Drug: MINT1526A
Sponsors:   Genentech;   Genentech
Recruiting - verified October 2011

Conditions:   Multiple Myeloma and Plasma Cell Neoplasm;   Thromboembolism
Interventions:   Other: enzyme-linked immunosorbent assay;   Other: laboratory biomarker analysis;   Other: medical chart review
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   UNC Lineberger Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Squamous Cell Carcinoma
Intervention:   Drug: Cetuximab and Lenalidomide
Sponsors:   University of Chicago;   University of Chicago;   Celgene Corporation
Recruiting - verified June 2011

Conditions:   HLRCC;   Metastatic Papillary RCC
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Myelodysplastic Syndrome;   MDS
Interventions:   Drug: Prednisone;   Drug: Lenalidomide
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Celgene Corporation
Recruiting - verified February 2012

Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Intervention:   Drug: Carboplatin, paclitaxel, and bevacizumab
Sponsors:   Columbia University;   Columbia University;   Genentech
Recruiting - verified October 2011

Condition:   Multiple Myeloma
Intervention:   Drug: Pomalidomide
Sponsors:   University of Arkansas;   University of Arkansas;   Celgene Corporation
Recruiting - verified February 2012

Conditions:   Renal Cell Cancer;   Kidney Cancer
Interventions:   Drug: Sunitinib;   Drug: Temsirolimus
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Pfizer
Recruiting - verified March 2012

Conditions:   Neoplasms;   Liver Metastases
Intervention:   Drug: EZN-2968
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Acoustic Schwannoma;   Adult Anaplastic Meningioma;   Adult Ependymoma;   Adult Grade I Meningioma;   Adult Grade II Meningioma;   Adult Meningeal Hemangiopericytoma;   Adult Papillary Meningioma;   Neurofibromatosis Type 1;   Neurofibromatosis Type 2;   Recurrent Adult Brain Tumor
Intervention:   Biological: bevacizumab
Sponsors:   Northwestern University;   Northwestern University
Recruiting - verified May 2012

Condition:   Chronic Lymphocytic Leukemia
Intervention:   Drug: Ofatumumab, Lenalidomide
Sponsors:   Medical University of South Carolina;   Medical University of South Carolina;   GlaxoSmithKline;   Celgene Corporation
Recruiting - verified November 2011

Condition:   Neuroblastoma
Intervention:   Drug: Bevacizumab, Irinotecan and Temozolomide
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Genentech
Recruiting - verified April 2012

Condition:   Advanced Cancer
Interventions:   Drug: Nab-paclitaxel;   Drug: Bevacizumab;   Drug: Gemcitabine
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Conditions:   Grade IV Malignant Glioma;   Glioblastoma Multiforme;   Gliosarcoma
Intervention:   Drug: AMG 102 plus Avastin (bevacizumab)
Sponsors:   Duke University;   Duke University;   Amgen
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: lenalidomide, bortezomib and dexamethasone;   Drug: Lenalidomide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: pemetrexed disodium
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Advanced Non-clear Cell Renal Cell Carcinoma
Interventions:   Drug: Everolimus;   Drug: Sunitinib
Sponsors:   Duke University;   Duke University;   Novartis;   Pfizer
Recruiting - verified February 2012

Condition:   Brain Cancer
Intervention:   Drug: Temozolomide, bevacizumab, lithium, radiation
Sponsors:   New York University School of Medicine;   New York University School of Medicine;   Genentech;   Ohio State University;   Atlantic Health System
Recruiting - verified February 2012

Conditions:   Ciliary Body and Choroid Melanoma, Medium/Large Size;   Ciliary Body and Choroid Melanoma, Small Size;   Iris Melanoma;   Recurrent Intraocular Melanoma
Interventions:   Biological: recombinant interferon alfa-2b;   Drug: dacarbazine;   Other: laboratory biomarker analysis
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center
Recruiting - verified December 2011

Conditions:   Epithelial Ovarian Cancer;   Primary Peritoneal Cancer;   Fallopian Tube Cancer
Interventions:   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Genentech
Recruiting - verified January 2012

Conditions:   Sarcoma;   Soft Tissue Sarcoma;   Locally Advanced Sarcoma;   Unresectable Sarcoma;   Metastatic Sarcoma
Intervention:   Drug: Bevacizumab, Gemcitabine, docetaxel and valproic acid
Sponsors:   University of Iowa;   University of Iowa;   Genentech
Recruiting - verified June 2011

Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer
Interventions:   Drug: lenalidomide;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Glioblastoma Multiforme
Intervention:   Drug: Bevacizumab
Sponsors:   Dartmouth-Hitchcock Medical Center;   Dartmouth-Hitchcock Medical Center;   Genentech
Recruiting - verified May 2012

Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
Intervention:   Drug: Irinotecan and Bevacizumab
Sponsors:   New York University School of Medicine;   New York University School of Medicine;   Genentech
Recruiting - verified March 2012

Conditions:   Glioblastoma;   Gliosarcoma;   Brain Tumor
Interventions:   Radiation: radiosurgery;   Biological: bevacizumab;   Drug: irinotecan hydrochloride
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center
Recruiting - verified March 2012

Condition:   Vestibular Schwannoma
Intervention:   Drug: Bevacizumab (Avastin)
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified September 2011

Condition:   Colorectal Cancer
Interventions:   Biological: cetuximab;   Biological: ramucirumab;   Drug: irinotecan hydrochloride
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: carboplatin;   Drug: oxaliplatin;   Drug: paclitaxel;   Procedure: quality-of-life assessment
Sponsors:   University College, London;   University College, London;   National Cancer Institute (NCI);   Gynecologic Oncology Group
Recruiting - verified December 2011

Conditions:   Myeloma;   Stem Cell Transplantation
Interventions:   Drug: Lenalidomide;   Drug: Melphalan
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified April 2012

Condition:   Waldenstrom's Macroglobulinemia
Interventions:   Drug: pomalidomide;   Drug: dexamethasone;   Drug: rituximab
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Celgene Corporation
Recruiting - verified June 2011

Condition:   Lymphoma
Interventions:   Drug: lenalidomide;   Drug: temsirolimus;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified November 2010

Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
Interventions:   Drug: everolimus;   Drug: lenalidomide;   Other: laboratory biomarker analysis;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: fluorescence in situ hybridization
Sponsors:   Mayo Clinic;   Mayo Clinic
Recruiting - verified March 2012

Condition:   Corneal Neovascularization
Interventions:   Drug: Avastin (bevacizumab);   Drug: 0.9% NaCl & Refresh Liquigel
Sponsors:   Massachusetts Eye and Ear Infirmary;   Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012

Conditions:   Brain Cancer;   Glioblastoma
Interventions:   Drug: Standard Dose Bevacizumab;   Drug: Low Dose Bevacizumab;   Drug: Lomustine
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Advanced Non-squamous Non-Small Cell Lung Cancer
Interventions:   Drug: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg;   Drug: Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg
Sponsors:   University of Chicago;   University of Chicago;   Genentech
Recruiting - verified June 2011

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Sunitinib and Dalteparin mono and combination therapy
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   Pfizer
Recruiting - verified March 2012

Condition:   Carcinoma
Interventions:   Drug: Intraperitoneal Oxaliplatin;   Drug: Intraperitoneal Oxaliplatin;   Drug: Intraperitoneal Oxaliplatin;   Drug: Intraperitoneal Oxaliplatin;   Drug: Intraperitoneal Oxaliplatin
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified December 2011

Conditions:   Nonneoplastic Condition;   Sarcoma
Interventions:   Drug: lenalidomide;   Other: laboratory biomarker analysis
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions:   Drug: carfilzomib;   Drug: cyclophosphamide;   Drug: thalidomide;   Drug: dexamethasone
Sponsors:   Mayo Clinic;   Mayo Clinic
Recruiting - verified April 2012

Condition:   Non-Hodgkin's Lymphoma
Interventions:   Drug: Lenalidomide;   Drug: ofatumumab
Sponsors:   University of Nebraska;   University of Nebraska;   Celgene Corporation;   GlaxoSmithKline
Recruiting - verified February 2012

Condition:   Advanced Cancers
Interventions:   Drug: HAI Abraxane;   Drug: Gemcitabine;   Drug: Bevacizumab;   Drug: Filgrastim
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Conditions:   Hemangiosarcoma;   Soft Tissue Sarcoma
Intervention:   Drug: Paclitaxel in combination with Bevacizumab
Sponsors:   Stanford University;   Stanford University;   Genentech
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Prednisone;   Drug: Dexamethasone
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Celgene Corporation
Recruiting - verified February 2012

Condition:   Tumor
Interventions:   Drug: Sunitinib;   Procedure: Surgery
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Pfizer
Recruiting - verified September 2011

Condition:   Refractory Multiple Myeloma
Interventions:   Drug: bendamustine hydrochloride;   Drug: lenalidomide;   Drug: dexamethasone
Sponsors:   Mayo Clinic;   Mayo Clinic
Recruiting - verified April 2012

Condition:   Multiple Myeloma
Interventions:   Biological: therapeutic autologous lymphocytes;   Drug: azacitidine;   Drug: lenalidomide
Sponsors:   Virginia Commonwealth University;   Virginia Commonwealth University;   National Cancer Institute (NCI);   Celgene Corporation
Recruiting - verified April 2012

Condition:   Colorectal Cancer
Interventions:   Drug: RAD011;   Drug: FOLFOX;   Drug: Bevacizumab
Sponsors:   University of Utah;   University of Utah;   Novartis
Recruiting - verified January 2012

Condition:   Non-squamous Non-small Cell Lung Cancer
Interventions:   Drug: ixabepilone;   Drug: bevacizumab
Sponsors:   Providence Health & Services;   Providence Health & Services;   Genentech;   Bristol-Myers Squibb
Recruiting - verified July 2011

Conditions:   Erythematotelangiectatic Rosacea;   Papulopustular Rosacea
Intervention:   Drug: Apremilast
Sponsors:   Columbia University;   Columbia University;   Celgene Corporation
Recruiting - verified February 2012

Condition:   Leukemia
Interventions:   Drug: 5-Azacytidine;   Drug: Lenalidomide
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
Recruiting - verified April 2012

Condition:   Anemia
Interventions:   Drug: Lenalidomide;   Other: Placebo
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified March 2012

Conditions:   Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions:   Genetic: mutation analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Drug: sunitinib malate;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: Azacitidine and Lenalidomide;   Drug: Azacitidine and Lenalidomide;   Drug: Azacitidine and Lenalidomide;   Drug: Azacitidine and Lenalidomide
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified October 2011

Condition:   Advanced Cancer
Interventions:   Drug: Dasatinib;   Drug: Bevacizumab;   Drug: Paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Chronic Lymphocytic Leukemia;   Leukemia
Intervention:   Drug: lenalidomide
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Celgene Corporation
Recruiting - verified April 2012

Conditions:   Endometrial Cancer;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Liver Cancer;   Lung Cancer;   Ovarian Cancer
Interventions:   Biological: bevacizumab;   Drug: temsirolimus;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: XELOX regimen;   Drug: hydroxychloroquine
Sponsors:   University of Medicine and Dentistry New Jersey;   University of Medicine and Dentistry New Jersey;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Cholangiocarcinoma
Intervention:   Drug: Gemcitabine, Capecitabine and Bevacizumab
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   Genentech
Recruiting - verified December 2011

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: Pemetrexed, Cisplatin, Bevacizumab
Sponsors:   Columbia University;   Columbia University
Recruiting - verified October 2011

Condition:   Refractory Solid Tumors in Children
Intervention:   Drug: combination of Irinotecan, vincristine, temozolomide and bevacizumab
Sponsors:   Children's Hospital Los Angeles;   Children's Hospital Los Angeles
Recruiting - verified October 2009

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Drug: veliparib
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Liver Cancer;   Advanced Cancer
Interventions:   Drug: Irinotecan;   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Cetuximab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified April 2012

Condition:   Endometrial Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: temsirolimus
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Melanoma (Skin)
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: everolimus;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: GDC-0941;   Drug: paclitaxel;   Drug: pemetrexed;   Drug: cisplatin
Sponsors:   Genentech;   Genentech
Recruiting - verified November 2011

Condition:   Head and Neck Cancer
Intervention:   Other: bevacizumab, cisplatin, cetuximab, radiation therapy
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Genentech
Recruiting - verified January 2012

Conditions:   Glioblastoma Multiforme;   Anaplastic Astrocytoma
Intervention:   Drug: Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University
Recruiting - verified March 2012

Condition:   Relapsed or Refractory Chronic Lymphocytic Leukemia
Intervention:   Drug: lenalidomide
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified February 2012

Condition:   Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: GDC-0941;   Drug: paclitaxel
Sponsors:   Genentech;   Genentech
Recruiting - verified October 2011

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Biological: cixutumumab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Malignant Glioma
Intervention:   Drug: bevacizumab and CPT-11 and Carboplatin
Sponsors:   Duke University;   Duke University
Recruiting - verified October 2011

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Biological: trastuzumab;   Drug: carboplatin;   Drug: docetaxel;   Other: laboratory biomarker analysis
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Advanced Non-Small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Bevacizumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Polycythemia Vera;   Thrombocythemia
Intervention:   Drug: CC-4047
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
Recruiting - verified April 2012

Condition:   Metastatic Prostate Cancer
Interventions:   Drug: Bevacizumab;   Drug: Lenalidomide;   Drug: Docetaxel;   Drug: Prednisone
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Advanced Cancers
Interventions:   Drug: HAI Oxaliplatin;   Drug: 5-FU;   Drug: Bevacizumab;   Drug: Cetuximab;   Drug: Leucovorin;   Drug: 5-FU;   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Testicular Cancer
Interventions:   Drug: Bevacizumab;   Drug: Gemcitabine;   Drug: Docetaxel;   Drug: Melphalan;   Drug: Carboplatin;   Drug: Mesna;   Drug: Ifosfamide;   Drug: Etoposide;   Procedure: Stem Cell Transplant
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Multiple Myeloma
Intervention:   Drug: Vorinostat, Lenalidomide, Bortezomib, Dexamethasone
Sponsors:   Emory University;   Emory University;   Merck;   Celgene Corporation
Recruiting - verified April 2012

Condition:   Colon Cancer With Metastases to the Liver
Interventions:   Device: LC bead loaded with Irinotecan;   Drug: FOLFOX6 and Avastin
Sponsors:   University of Louisville;   University of Louisville;   Biocompatibles UK Ltd
Recruiting - verified November 2011

Conditions:   Advanced Non-small Cell Lung Cancer;   Postmenopausal Women
Interventions:   Drug: fulvestrant (Faslodex);   Drug: anastrozole (Arimidex);   Drug: Bevacizumab (Avastin);   Drug: Best standard of care
Sponsors:   University of Pittsburgh;   University of Pittsburgh
Recruiting - verified January 2012

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Azacitidine
Sponsors:   University of Kansas;   University of Kansas;   Celgene Corporation
Recruiting - verified October 2011

Conditions:   Glioblastoma Multiforme;   Malignant Gliomas;   Anaplastic Gliomas
Intervention:   Drug: Sutent (sunitinib)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Sarcoma, Kaposi
Interventions:   Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Bevacizumab;   Drug: Ixempra (Ixbepilone [BMS-247550]
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Biological: DC vaccine;   Drug: Bevacizumab;   Biological: IL-2;   Biological: IFN
Sponsors:   Dartmouth-Hitchcock Medical Center;   Dartmouth-Hitchcock Medical Center;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions:   Drug: Lenalidomide;   Drug: Chlorambucil
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified September 2011

Conditions:   Cancer;   Colon Cancer;   Colorectal Cancer;   Fever;   Locally Advanced;   Metastatic Colorectal Cancer;   Neutropenia;   Rectal Cancer
Interventions:   Drug: Pegfilgrastim;   Drug: Placebo
Sponsors:   Amgen;   Amgen
Recruiting - verified January 2012

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: Lenalidomide;   Drug: Fludarabine;   Drug: Rituximab;   Drug: Thymoglobulin;   Procedure: Stem Cell Transplantation;   Drug: Bendamustine;   Drug: Allopurinol
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
Recruiting - verified May 2012

Condition:   Pulmonary Veno Occlusive Disease
Intervention:   Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)
Sponsors:   Children's Hospital Boston;   Children's Hospital Boston
Recruiting - verified June 2011

Conditions:   Newly Diagnosed High-Grade Gliomas;   Diffuse Intrinsic Pontine Glioma
Interventions:   Drug: Temozolomide;   Drug: Bevacizumab;   Drug: Irinotecan
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Children's Hospital Medical Center, Cincinnati;   Genentech
Recruiting - verified February 2012

Conditions:   Leukemia;   Amyloidosis
Interventions:   Drug: Lenalidomide;   Drug: Melphalan;   Drug: Dexamethasone
Sponsors:   Stanford University;   Stanford University;   Celgene Corporation
Recruiting - verified May 2012

Condition:   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: Ixabepilone;   Drug: Sunitinib;   Other: Angiogenesis Biomarker Analysis;   Other: Pharmacokinetic Design
Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center;   Bristol-Myers Squibb;   Pfizer
Recruiting - verified March 2012

Conditions:   Sarcoma;   Leiomyosarcoma;   Malignant Fibrous;   Histiocytoma;   Angiosarcoma
Intervention:   Drug: gemcitabine and docetaxel with bevacizumab
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Genentech
Recruiting - verified February 2012

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: everolimus;   Other: placebo
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Sunitinib;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Sunitinib
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Pfizer
Recruiting - verified March 2012

Condition:   Neuroblastoma
Interventions:   Drug: Bevacizumab;   Drug: cyclophosphamide;   Drug: zoledronic acid
Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Brain Cancer;   Pediatric Cancers
Interventions:   Drug: Bevacizumab;   Drug: Lapatinib
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified March 2012

Conditions:   Recurrent Glioblastoma Multiforme;   Recurrent Gliosarcoma
Intervention:   Drug: temozolomide and bevacizumab
Sponsors:   Center for Neurosciences, Tucson;   Center for Neurosciences, Tucson;   Genentech
Recruiting - verified June 2011

Condition:   Liver Cancer
Interventions:   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Drug: sorafenib tosylate
Sponsors:   Medical University of South Carolina;   Medical University of South Carolina
Recruiting - verified June 2010

Conditions:   Glial Cell Tumors;   Malignant Gliomas;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Gliomatosis Cerebri;   Gliosarcoma;   Brainstem Glioma
Interventions:   Drug: Valproic acid;   Drug: Bevacizumab;   Radiation: Radiation therapy
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine
Recruiting - verified February 2012

Condition:   Central Nervous System Tumors
Interventions:   Drug: Bevacizumab;   Drug: Irinotecan;   Drug: Temozolomide
Sponsors:   All Children's Hospital;   All Children's Hospital;   V Foundation
Recruiting - verified June 2011

Condition:   Non-Small Cell Lung Cancer
Interventions:   Biological: Imprime PGG® Injection;   Biological: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin
Sponsors:   Biothera;   Biothera
Recruiting - verified March 2012

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: FOLFOX regimen;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: ursodiol;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: positron emission tomography (PET)
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Myelodysplastic Syndrome
Intervention:   Drug: Lenalidomide
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified January 2012

Conditions:   Chronic Lymphocytic Leukemia;   Non-Hodgkin's Lymphoma
Interventions:   Drug: bendamustine and lenalidomide;   Drug: BL-NHL;   Drug: BLR-CLL;   Drug: BLR-NHL
Sponsors:   Georgetown University;   Georgetown University;   Celgene Corporation;   Cephalon
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Malignant Glioma
Interventions:   Drug: LBH589;   Drug: bevacizumab
Sponsors:   Dana-Farber Cancer Institute;   Patrick Y. Wen, MD;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Northwestern University;   University of Virginia;   Genentech;   Novartis
Recruiting - verified February 2012

Condition:   Sarcoma, Soft Tissue
Intervention:   Drug: Sunitinib
Sponsors:   Columbia University;   Columbia University
Recruiting - verified October 2011

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Biological: pegfilgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Kidney Cancer
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: sunitinib malate
Sponsors:   University of Medicine and Dentistry New Jersey;   University of Medicine and Dentistry New Jersey;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Leukemia
Interventions:   Drug: lenalidomide;   Biological: bystander vaccine
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Celgene Corporation
Recruiting - verified February 2012

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: Lenalidomide, Decitabine
Sponsors:   Duke University;   Duke University;   Celgene Corporation
Recruiting - verified February 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: bevacizumab;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: pentostatin
Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Cancer
Interventions:   Drug: hydroxychloroquine;   Drug: sunitinib malate
Sponsors:   University of Medicine and Dentistry New Jersey;   University of Medicine and Dentistry New Jersey;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Conditions:   Burns;   Electric Burns
Intervention:   Drug: R-Pdf/Gbb 0.01% gel
Sponsors:   American Scitech International;   American Scitech International;   Johnson & Johnson
Not yet recruiting - verified July 2011

Condition:   Multiple Myeloma
Interventions:   Procedure: Stem cell transplant x 1 or x 2;   Drug: lenalidomide and dexamethasone
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Tufts Medical Center;   Lahey Clinic
Recruiting - verified January 2012

Conditions:   Breast Cancer;   Breast Neoplasms;   Breast Tumors;   Cancer;   Locally Recurrent and Metastatic Breast Cancer;   Metastases;   Metastatic Cancer;   Oncology;   Solid Tumors;   Tumors
Interventions:   Drug: AMG 386 15 mg/kg, Capecitabine and Lapatinib;   Drug: AMG 386 15mg/kg, Paclitaxel and Trastuzumab;   Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab;   Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib;   Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab;   Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
Sponsors:   Amgen;   Amgen
Recruiting - verified March 2012

Condition:   Cervical Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: paclitaxel;   Drug: topotecan hydrochloride
Sponsors:   National Cancer Institute (NCI);   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Multiple Myeloma;   Plasma Cell Neoplasm
Interventions:   Drug: Lenalidomide & Dexamethasone;   Drug: Lenalidomide & Dexamethasone;   Drug: Lenalidomide & Dexamethasone
Sponsors:   PrECOG, LLC.;   PrECOG, LLC.;   Celgene Corporation
Recruiting - verified April 2012

Condition:   Melanoma
Interventions:   Drug: Bevacizumab Plus Ipilimumab;   Drug: Bevacizumab Plus Ipilimumab;   Drug: Bevacizumab Plus Ipilimumab;   Drug: Bevacizumab Plus Ipilimumab
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Genentech;   Bristol-Myers Squibb
Recruiting - verified October 2011

Condition:   Solid Tumor
Interventions:   Drug: Bevacizumab;   Drug: Temozolomide;   Drug: Vincristine sulfate;   Drug: Irinotecan;   Drug: Cefixime or Cefpodoxime
Sponsors:   Children's Hospital Medical Center, Cincinnati;   Children's Hospital Medical Center, Cincinnati
Recruiting - verified February 2012

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Stomach Cancer;   Gastric (Stomach) Cancer;   Neoplasm of Cardioesophageal Junction;   Gastrointestinal Stromal Tumor (GIST)
Interventions:   Drug: bevacizumab;   Drug: carboplatin;   Drug: capecitabine
Sponsors:   Stanford University;   Pamela L. Kunz;   Genentech
Recruiting - verified February 2012

Condition:   Multiple Myeloma
Interventions:   Drug: Lenalidomide;   Drug: Dexamethasone
Sponsors:   University of Pittsburgh;   University of Pittsburgh
Recruiting - verified May 2012

Condition:   Prostate Cancer
Interventions:   Drug: Androgen Deprivation Therapy;   Drug: bicalutamide;   Drug: bevacizumab
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Genentech;   Beth Israel Deaconess Medical Center;   Brigham and Women's Hospital;   Cancer Institute of New Jersey
Recruiting - verified February 2012

Condition:   Breast Cancer
Intervention:   Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Sponsors:   University of Tennessee Cancer Institute;   University of Tennessee Cancer Institute;   National Comprehensive Cancer Network;   Celgene Corporation;   Genentech
Recruiting - verified February 2012

Condition:   B-cell Chronic Lymphocytic Leukemia
Interventions:   Drug: Lenalidomide;   Drug: Placebo
Sponsors:   Celgene Corporation;   Celgene Corporation
Recruiting - verified May 2012

Condition:   Brain Neoplasms
Intervention:   Drug: Ferumoxytol
Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI);   AMAG Pharmaceuticals, Inc.
Recruiting - verified March 2012

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Biological: Bevacizumab;   Biological: Bevacizumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company
Recruiting - verified May 2012

Conditions:   Recurrent or Refractory Solid Tumors;   CNS Malignancies
Interventions:   Drug: Bevacizumab;   Drug: Everolimus
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   Novartis Pharmaceuticals
Recruiting - verified December 2011

Conditions:   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions:   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: immunohistochemistry staining method;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Multiple Myeloma
Interventions:   Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
Sponsors:   University of Arkansas;   University of Arkansas;   Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: lenalidomide;   Drug: vorinostat;   Procedure: quality-of-life assessment;   Procedure: Correlative studies
Sponsors:   Ohio State University Comprehensive Cancer Center;   Ohio State University Comprehensive Cancer Center;   Merck
Recruiting - verified November 2011

Condition:   Hodgkin Lymphoma
Intervention:   Drug: Avastin
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute;   Genentech
Recruiting - verified November 2011

Condition:   Lymphoma
Interventions:   Biological: PEG-interferon alfa-2b;   Procedure: UV light therapy
Sponsors:   Northwestern University;   Northwestern University;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Head and Neck Cancer
Interventions:   Drug: docetaxel;   Drug: erlotinib hydrochloride;   Genetic: fluorescence in situ hybridization;   Genetic: polymerase chain reaction;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: therapeutic conventional surgery;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Procedure: Nephrectomy
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Pfizer
Recruiting - verified May 2012

Condition:   Cancer
Interventions:   Drug: Bevacizumab;   Drug: Cetuximab;   Drug: Pemetrexed;   Radiation: Radiation therapy
Sponsors:   University of Pittsburgh;   University of Pittsburgh;   Eli Lilly and Company;   Genentech
Recruiting - verified April 2012

Conditions:   Type 2 Diabetes Mellitus;   Impaired Glucose Tolerance (Prediabetes)
Interventions:   Behavioral: Aerobic exercise training;   Behavioral: Detraining (cessation of exercise)
Sponsors:   Department of Veterans Affairs;   Department of Veterans Affairs;   University of Maryland
Recruiting - verified March 2012

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel;   Drug: Vorinostat, Bevacizumab, Carboplatin, Paclitaxel
Sponsors:   Penn State University;   Penn State University
Recruiting - verified July 2011

Condition:   Lymphoma
Interventions:   Drug: Lenalidomide;   Drug: Rituximab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
Recruiting - verified December 2011

Conditions:   Neurofibromatosis Type 1;   Plexiform Neurofibroma
Intervention:   Drug: PEG-interferon alfa-2b
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Metastatic Melanoma;   Cutaneous Melanoma
Interventions:   Drug: Interferon alpha;   Drug: KW2871;   Drug: KW2871;   Drug: interferon alpha;   Drug: KW2871;   Drug: Interferon alpha
Sponsors:   Ludwig Institute for Cancer Research;   Ludwig Institute for Cancer Research;   Life Sciences Pharmaceuticals
Recruiting - verified April 2012

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: dexamethasone;   Drug: lenalidomide;   Drug: melphalan
Sponsors:   Boston Medical Center;   Boston Medical Center
Recruiting - verified February 2012

Condition:   Lymphoma
Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Malignant Gliomas
Interventions:   Drug: Irinotecan;   Drug: Lenalidomide
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation
Recruiting - verified January 2012

Conditions:   Papillary Thyroid Cancer;   Follicular Thyroid Cancer;   Differentiated Thyroid Cancer
Intervention:   Drug: SU011248, Sutent
Sponsors:   Washington Hospital Center;   Washington Hospital Center;   Pfizer
Recruiting - verified April 2012

Conditions:   Osteosarcoma;   Malignant Fibrous Histiocytoma (MFH) of Bone
Interventions:   Biological: Bevacizumab;   Drug: Chemotherapy (Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide)
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   Genentech;   National Institutes of Health (NIH)
Recruiting - verified June 2011

Conditions:   Refractory Solid Tumors;   Leukemia
Interventions:   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Cyclophosphamide
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
Recruiting - verified January 2012

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: ABI-007l albumin-stabilized nanoparticle formulation
Sponsors:   Loyola University;   Loyola University;   Genentech
Recruiting - verified September 2011

Condition:   Non-Small Cell Lung Cancer
Interventions:   Drug: Paclitaxel;   Drug: Gemcitabine;   Biological: Avastin
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Genentech
Recruiting - verified August 2011

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: bortezomib;   Drug: dexamethasone;   Drug: lenalidomide
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   Mantle Cell Lymphoma
Interventions:   Drug: Rituximab;   Drug: Bortezomib;   Drug: Lenalidomide
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Millennium Pharmaceuticals, Inc.;   Celgene Corporation
Recruiting - verified November 2011

Condition:   Chronic Lymphocytic Leukemia
Intervention:   Drug: Lenalidomide
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Brain Cancer
Intervention:   Drug: Palonosetron (Aloxi) and Dexamethasone
Sponsors:   Duke University;   Duke University;   Eisai Inc.;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Biological: Dendritic Cell/Tumor Fusion Vaccine;   Drug: Interleukin-12;   Drug: Interleukin-12
Sponsors:   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Harvard University;   Department of Defense;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Pancreatic Cancer
Interventions:   Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Capecitabine;   Radiation: Radiation Therapy
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Genentech
Recruiting - verified May 2012

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Doxil;   Drug: Carboplatin;   Drug: Bevacizumab
Sponsors:   University of Medicine and Dentistry New Jersey;   University of Medicine and Dentistry New Jersey;   Cancer Institute of New Jersey
Recruiting - verified October 2011

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   CNS Cancer;   Meningioma;   Intracranial Hemangiopericytoma;   Hemangioblastoma;   Neurofibromatosis
Intervention:   Drug: Sunitinib
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Dana-Farber Cancer Institute;   University of Virginia;   University of Pittsburgh;   Pfizer
Recruiting - verified November 2011

Conditions:   Mucosal Melanoma;   Acral/Lentiginous Melanoma
Intervention:   Drug: SU011248
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Beth Israel Deaconess Medical Center;   Massachusetts General Hospital;   Pfizer
Recruiting - verified October 2011

Condition:   Prostate Cancer
Intervention:   Drug: RAD001, Docetaxel, Bevacizumab
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center;   Novartis;   Genentech;   University of Southern California
Recruiting - verified May 2012

Condition:   Recurrent Glioblastoma
Interventions:   Drug: enzastaurin;   Drug: bevacizumab
Sponsors:   Eli Lilly and Company;   Eli Lilly and Company;   Genentech
Recruiting - verified October 2011

Condition:   Breast Cancer
Interventions:   Drug: sunitinib;   Drug: capecitabine;   Radiation: WBRT
Sponsors:   Baylor Breast Care Center;   Baylor Breast Care Center
Recruiting - verified January 2012

Condition:   Neuroendocrine Carcinoma
Interventions:   Biological: bevacizumab;   Biological: recombinant interferon alfa-2b;   Drug: octreotide acetate
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   Renal Cell Carcinoma;   Neoplasm Metastases
Interventions:   Drug: Gemcitabine;   Drug: Sunitinib
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Pfizer;   Beth Israel Deaconess Medical Center;   Dana-Farber Cancer Institute
Recruiting - verified March 2012

Condition:   Advanced Cancer
Interventions:   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Erlotinib;   Drug: Trastuzumab;   Drug: Lapatinib;   Drug: Sunitinib;   Drug: Cetuximab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Malignant Melanoma
Interventions:   Drug: Peginterferon alpha-2b, non- pegylated interferon alpha-2b;   Drug: Temozolomide, peginterferon alpha-2b
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   Schering-Plough
Recruiting - verified January 2012

Condition:   Chronic Lymphocytic Leukemia
Intervention:   Drug: lenalidomide, fludarabine and rituximab
Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Celgene Corporation;   Genentech
Recruiting - verified November 2011

Condition:   Advanced Cancers
Intervention:   Behavioral: Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Advanced Cancer
Interventions:   Drug: Valproic Acid;   Drug: Bevacizumab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified February 2012

Conditions:   Inflammatory Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions:   Drug: sunitinib malate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: flow cytometry
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Condition:   Solid Tumors
Interventions:   Drug: Dasatinib;   Drug: Erlotinib;   Drug: Lapatinib;   Drug: Lenalidomide;   Drug: Sorafenib;   Drug: Sunitinib;   Drug: Valproic Acid
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified December 2011

Condition:   Peritoneal Cancer
Interventions:   Drug: Bevacizumab;   Drug: Oxaliplatin;   Drug: Paclitaxel
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Breast Cancer
Interventions:   Drug: Abraxane;   Drug: Bevacizumab;   Drug: Carboplatin
Sponsors:   Duke University;   Duke University;   Genentech
Recruiting - verified June 2011

Condition:   Lung Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: etoposide;   Drug: sunitinib malate
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Conditions:   Esophageal Neoplasms;   Stomach Neoplasms;   Neoplasm Metastasis
Intervention:   Drug: capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)
Sponsors:   Duke University;   Duke University;   Hoffmann-La Roche;   Sanofi-Aventis;   Genentech
Recruiting - verified December 2011

Condition:   Peritoneal Cancer
Interventions:   Drug: Sorafenib;   Biological: Bevacizumab;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Procedure: dynamic contract-enhanced magnetic resonance imaging;   Procedure: needle biopsy;   Procedure: positron emission tomography;   Radiation: fludeoxyglucose F 18
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Breast Cancer
Interventions:   Drug: Trastuzumab;   Drug: Bevacizumab;   Drug: Docetaxel
Sponsors:   Ohio State University Comprehensive Cancer Center;   Ohio State University Comprehensive Cancer Center;   Genentech;   Case Comprehensive Cancer Center;   University of Pittsburgh
Recruiting - verified April 2012

Conditions:   Metastatic Breast Cancer;   Advanced Breast Cancer;   Gastrointestinal Stromal Tumor;   Hepatocellular Carcinoma;   Metastasizing Breast Cancer (F);   Metastatic Castration-Resistant Prostrate Cancer;   Metastatic Renal Cell Cancer;   Non Small Cell Lung Cancer;   Pancreatic Islet Cell Carcinoma
Intervention:   Drug: sunitinib
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Conditions:   Advanced Malignancy;   Lymphoma;   Myeloma;   Solid Tumors
Interventions:   Drug: Bevacizumab;   Drug: Bortezomib
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Condition:   Plexiform Neurofibroma
Intervention:   Drug: PEG-Intron
Sponsors:   Children's Hospital of Pittsburgh;   Children's Hospital of Pittsburgh;   National Cancer Institute (NCI)
Recruiting - verified January 2008

Condition:   Kidney Neoplasms
Interventions:   Drug: Sunitinib malate;   Other: Placebo
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   Leukemia
Interventions:   Biological: GM-K562 cell vaccine;   Biological: recombinant interferon alfa;   Biological: sargramostim
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine tartrate
Sponsors:   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
Recruiting - verified February 2012

Condition:   Renal Cell Cancer
Interventions:   Drug: Bevacizumab and Bortezomib;   Drug: Bevacizumab and Bortezomib
Sponsors:   USC/Norris Comprehensive Cancer Center;   USC/Norris Comprehensive Cancer Center
Recruiting - verified May 2012

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified June 2011

Condition:   Pancreatic Cancer
Interventions:   Biological: recombinant interferon alfa;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Procedure: hyperthermia treatment
Sponsors:   National Cancer Institute (NCI);   The University of Texas Health Science Center, Houston
Recruiting - verified December 2008

Condition:   Central Nervous System Neoplasms
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   Kaposi's Sarcoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2012